These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 29726819)
21. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line. Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258 [TBL] [Abstract][Full Text] [Related]
22. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234 [TBL] [Abstract][Full Text] [Related]
23. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review. Gautam N; Kaur M; Kaur S J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698 [TBL] [Abstract][Full Text] [Related]
24. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Mahmoud F; Shields B; Makhoul I; Hutchins LF; Shalin SC; Tackett AJ Cancer Biol Ther; 2016 Jun; 17(6):579-91. PubMed ID: 27105109 [TBL] [Abstract][Full Text] [Related]
25. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Wan L; Xu K; Wei Y; Zhang J; Han T; Fry C; Zhang Z; Wang YV; Huang L; Yuan M; Xia W; Chang WC; Huang WC; Liu CL; Chang YC; Liu J; Wu Y; Jin VX; Dai X; Guo J; Liu J; Jiang S; Li J; Asara JM; Brown M; Hung MC; Wei W Mol Cell; 2018 Jan; 69(2):279-291.e5. PubMed ID: 29351847 [TBL] [Abstract][Full Text] [Related]
26. MUC1-C activates EZH2 expression and function in human cancer cells. Rajabi H; Hiraki M; Tagde A; Alam M; Bouillez A; Christensen CL; Samur M; Wong KK; Kufe D Sci Rep; 2017 Aug; 7(1):7481. PubMed ID: 28785086 [TBL] [Abstract][Full Text] [Related]
27. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro. Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085 [TBL] [Abstract][Full Text] [Related]
28. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis. Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890 [TBL] [Abstract][Full Text] [Related]
29. EZH2 as a potential target in cancer therapy. McCabe MT; Creasy CL Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487 [TBL] [Abstract][Full Text] [Related]
30. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299 [No Abstract] [Full Text] [Related]
31. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background. Gall TroĊĦelj K; Novak Kujundzic R; Ugarkovic D Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242 [TBL] [Abstract][Full Text] [Related]
32. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2. Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470 [TBL] [Abstract][Full Text] [Related]
33. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells. Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008 [TBL] [Abstract][Full Text] [Related]
34. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes. Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165 [TBL] [Abstract][Full Text] [Related]
35. Targeting EZH2 as cancer therapy. Hanaki S; Shimada M J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735 [TBL] [Abstract][Full Text] [Related]
36. EZH2: a novel target for cancer treatment. Duan R; Du W; Guo W J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346 [TBL] [Abstract][Full Text] [Related]
37. [EZH2 is therapeutic target for personalized treatment in multiple myeloma]. Herviou L; Cavalli G; Moreaux J Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976 [TBL] [Abstract][Full Text] [Related]
38. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457 [TBL] [Abstract][Full Text] [Related]
39. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Italiano A Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746 [TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]